Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
9.34 CHF | -0.32% | +0.97% | -4.79% |
Apr. 17 | Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis | MT |
Mar. 27 | Santhera Pharmaceuticals Wins Priority Review for Duchenne Muscular Dystrophy Drug in China | MT |
- Stock Market
- Equities
- SANN Stock
- News Santhera Pharmaceuticals Holding AG